Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SPS vs KOMZIFTI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.
KOMZIFTI (asciminib) is a potent and selective ABL/BCR-ABL1 myristoyl pocket (STAMP) inhibitor. It binds to the myristoyl pocket of the ABL1 protein, stabilizing the inactive conformation and inhibiting BCR-ABL1 kinase activity, including many imatinib-resistant mutants.
Treatment of hyperkalemia
Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors (TKIs).,Treatment of adult patients with Ph+ CML-CP with the T315I mutation.
15-60 g orally 1-4 times daily; administer as a suspension in water or juice. Alternatively, 30-50 g rectally as a retention enema every 6 hours.
Intravenous: 500 mg every 6 hours or 1 g every 12 hours. Oral: 500 mg every 8 hours or 1 g every 12 hours.
Not applicable; SPS acts locally in the gastrointestinal tract and does not undergo systemic absorption. No terminal half-life can be defined.
Terminal elimination half-life 12-18 hours; clinically relevant for dosing interval adjustment in renal impairment
SPS is not absorbed systemically and is excreted unchanged in the feces.
Primarily metabolized via CYP3A4 and UGT2B17. Minor routes: CYP2C8, CYP2D6, and amide hydrolysis.
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that is not absorbed systemically. It is excreted entirely in the feces, with no renal or biliary elimination. The resin-bound potassium is eliminated via the gastrointestinal tract.
Renal excretion 70-80% as unchanged drug; biliary/fecal 15-20%
Not applicable; SPS is not absorbed and does not bind to plasma proteins.
95% bound to albumin
Not applicable; SPS remains within the gastrointestinal lumen and does not distribute into body tissues. Reported Vd is negligible.
0.5-0.8 L/kg; indicates moderate tissue distribution
Oral: 0% (not absorbed); rectal: 0% (not absorbed). SPS acts locally without systemic availability.
Oral: 60-70%
No specific dose adjustment is recommended based on GFR. Use with caution in patients with renal impairment due to risk of electrolyte disturbances (e.g., hypernatremia, hypokalemia).
Cr Cl >50 m L/min: no adjustment; Cr Cl 30-50 m L/min: 500 mg every 12 hours; Cr Cl 10-29 m L/min: 500 mg every 24 hours; Cr Cl <10 m L/min or hemodialysis: 500 mg every 48 hours.
No dose adjustment required for hepatic impairment. Monitor serum electrolytes and fluid balance in patients with hepatic disease.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or consider alternative.
Children (2-12 years): 0.5-2 g/kg/day divided every 4-6 hours; maximum 30 g/day. Administer orally or rectally as per adult guidance.
Children 2-12 years: intravenous 12-15 mg/kg every 6 hours, maximum 2 g/day; oral 10-15 mg/kg every 8 hours, maximum 1.5 g/day.
Use lowest effective dose; monitor electrolyte levels and renal function more frequently due to age-related decline in renal function and increased risk of electrolyte imbalance.
No specific dose adjustment based on age alone; monitor renal function and adjust per renal impairment guidelines.
No FDA black box warning.
None.
Risk of intestinal necrosis, particularly with concomitant use of sorbitol,Electrolyte disturbances (e.g., hypokalemia, hypocalcemia, hypernatremia),Use with caution in patients with gastrointestinal disorders or postoperative patients
Cardiovascular events, including arterial occlusive events (e.g., myocardial infarction, stroke).,Pancreatic toxicity (elevated lipase/amylase, pancreatitis).,Hepatotoxicity (elevated transaminases, bilirubin).,Myelosuppression (anemia, neutropenia, thrombocytopenia).,Fetal harm: Can cause fetal harm; verify pregnancy status before initiation.
Hypokalemia,Obstructive bowel disease,Neonates with reduced gut motility (postoperative or drug-induced),Concurrent use with sorbitol
None identified.
Avoid high-potassium foods such as bananas, oranges, tomatoes, potatoes, and spinach to prevent excessive potassium intake. SPS may bind to some foods, but no specific food restrictions beyond potassium-rich foods are required. Do not mix SPS with fruit juices; use only water or simple syrup.
Avoid grapefruit and grapefruit juice due to risk of increased asciminib exposure. No other food restrictions.
SPS (sodium polystyrene sulfonate) is not absorbed systemically; therefore, no direct fetal risk is expected. However, electrolyte disturbances (e.g., hypokalemia, hypocalcemia) from maternal use could indirectly affect the fetus. First trimester: No known teratogenic effects. Second/Third trimester: Risk of maternal electrolyte imbalance may impact fetal development. Use only if clearly needed.
First trimester: Increased risk of congenital malformations, particularly neural tube defects and facial clefts, based on animal studies and limited human data. Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and neurodevelopmental impairment. Avoid use unless benefit outweighs risk.
Excretion into breast milk is unlikely due to non-absorbable nature. M/P ratio not applicable. Considered compatible with breastfeeding, but monitor infant for electrolyte disturbances if maternal use is prolonged.
Unknown if excreted in breast milk; M/P ratio not established. Potential for serious adverse effects in nursing infants. Discontinue breastfeeding or discontinue drug.
No pharmacokinetic changes expected due to lack of absorption. Standard dosing may be used, but monitor electrolytes frequently due to altered renal function and volume of distribution in pregnancy. Dose adjustments are not required, but lower doses may suffice to avoid severe electrolyte shifts.
Increased clearance during pregnancy may require 20-40% dose escalation. Monitor therapeutic drug levels; adjust to maintain target concentration.
SPS (sodium polystyrene sulfonate) is a potassium-lowering resin that exchanges sodium for potassium in the GI tract. Administer orally or as a retention enema. Monitor for hypokalemia, hypomagnesemia, and sodium overload. Contraindicated in patients with bowel obstruction, severe constipation, or postoperative ileus due to risk of intestinal necrosis. Use with caution in patients on NSAIDs or with risk of colonic necrosis. Do not mix with sorbitol; use of sorbitol increases risk of intestinal necrosis. Monitor serum potassium levels frequently.
KOMZIFTI (asciminib) is a BCR-ABL1 inhibitor specific for the ABL myristoyl pocket, effective against T315I mutant CML. Dose reduction required in hepatic impairment (Child-Pugh A/B/C). QT interval monitoring recommended due to concentration-dependent QT prolongation. Avoid concurrent use with strong CYP3A4 inhibitors or inducers.
Take this medication exactly as prescribed, usually 1 to 4 times a day.,Do not mix SPS with orange juice or other fruit juices; it should be mixed with water or syrup.,This medication may cause constipation, so drink plenty of fluids and eat high-fiber foods.,If you experience severe constipation, severe abdominal pain, vomiting, or blood in vomit or stool, seek medical attention immediately.,Avoid taking other medications within 3 hours of SPS as it may bind to them and reduce their effectiveness.,Inform your doctor if you have a history of bowel obstruction, constipation, or kidney disease.,Do not use sorbitol or other laxatives with SPS unless directed by your doctor.
Take KOMZIFTI exactly as prescribed, with or without food.,Do not crush or chew tablets; swallow whole.,Report any signs of pancreatitis (severe abdominal pain), hypertension, or thrombotic events immediately.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception if of childbearing potential; avoid pregnancy.,Regular monitoring of blood counts, liver function, and ECG is required.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SPS vs KOMZIFTI, answered by our medical review team.
SPS is a Potassium Binder that works by SPS (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.. KOMZIFTI is a Potassium Binder that works by KOMZIFTI (asciminib) is a potent and selective ABL/BCR-ABL1 myristoyl pocket (STAMP) inhibitor. It binds to the myristoyl pocket of the ABL1 protein, stabilizing the inactive conformation and inhibiting BCR-ABL1 kinase activity, including many imatinib-resistant mutants.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SPS and KOMZIFTI depend on the specific clinical indication. These are both Potassium Binder agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SPS is: 15-60 g orally 1-4 times daily; administer as a suspension in water or juice. Alternatively, 30-50 g rectally as a retention enema every 6 hours.. The standard adult dose of KOMZIFTI is: Intravenous: 500 mg every 6 hours or 1 g every 12 hours. Oral: 500 mg every 8 hours or 1 g every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SPS and KOMZIFTI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SPS is classified as Category C. SPS (sodium polystyrene sulfonate) is not absorbed systemically; therefore, no direct fetal risk is expected. However, electrolyte disturbances (e.g., hypokalemia, hypocalcemia) fr. KOMZIFTI is classified as Category C. First trimester: Increased risk of congenital malformations, particularly neural tube defects and facial clefts, based on animal studies and limited human data. Second/third trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.